HNSCC
MCID: SQM013
MIFTS: 70

Squamous Cell Carcinoma, Head and Neck (HNSCC) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Squamous Cell Carcinoma, Head and Neck

About this section

Aliases & Descriptions for Squamous Cell Carcinoma, Head and Neck:

Name: Squamous Cell Carcinoma, Head and Neck 52 12
Squamous Cell Carcinoma of the Head and Neck 35 11 48 25 70 13 68
Head and Neck Squamous Cell Carcinoma 11 48 25 54 13
Hnscc 48 25 54 70 50
Carcinoma, Squamous Cell of Head and Neck 48 39
Squamous Cell Carcinoma of Head and Neck 54 27
 
Head and Neck Cancer 48 38
Squamous Cell Carcinoma, Head and Neck, Somatic 52
Squamous Cell Carcinomas of Head and Neck 11
Carcinoma of the Head and Neck 11
Cancer of Head and Neck 68
Scchn 25

Characteristics:

Orphanet epidemiological data:

54
head and neck squamous cell carcinoma:
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: All ages

HPO:

64
squamous cell carcinoma, head and neck:
Inheritance: autosomal recessive inheritance

Classifications:



External Ids:

OMIM52 275355
Disease Ontology11 DOID:5520
NCIt45 C34447
Orphanet54 ORPHA67037
MESH via Orphanet40 C535575
UMLS via Orphanet69 C1168401
MedGen37 C1168401

Summaries for Squamous Cell Carcinoma, Head and Neck

About this section
MedlinePlus:38 Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. most begin in the moist tissues that line the mouth, nose, and throat. symptoms include a lump or sore that does not heal a sore throat that does not go away trouble swallowing a change or hoarseness in the voice head and neck cancers are twice as common in men. using tobacco or alcohol increases your risk. in fact, around 75 percent of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. infection with hpv is a risk factor for some head and neck cancers. to diagnose head and neck cancer, your doctor will do a physical exam and diagnostic tests. you will have a biopsy, where a sample of tissue is taken out and examined under a microscope. it is the only test that can tell for sure if you have cancer. if found early, these cancers are often curable. treatments may include surgery, radiation therapy, chemotherapy, or a combination. treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. nih: national cancer institute

MalaCards based summary: Squamous Cell Carcinoma, Head and Neck, also known as squamous cell carcinoma of the head and neck, is related to oral cancer and thyroid cancer, and has symptoms including coughing, halitosis and snoring. An important gene associated with Squamous Cell Carcinoma, Head and Neck is PTEN (Phosphatase And Tensin Homolog), and among its related pathways are HIF1Alpha Pathway and Transcription Ligand-dependent activation of the ESR1/SP pathway. Affiliated tissues include skin, testes and salivary gland, and related mouse phenotypes are Decreased viability in esophageal squamous lineage and embryo.

Disease Ontology:11 A head and neck carcinoma that has material basis in squamous cells that line the moist, mucosal surfaces inside the head and neck.

Genetics Home Reference:25 Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat.

NIH Rare Diseases:48 Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). these squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. at least 75 % of head and neck cancers are caused by tobacco and alcohol use. infection with cancer-causing types of human papillomavirus (hpv), especially hpv-16, is a risk factor for some types of head and neck cancers. the symptoms of head and neck cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. treatment for head and neck cancer can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments. last updated: 8/3/2015

UniProtKB/Swiss-Prot:70 Squamous cell carcinoma of the head and neck: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.

Description from OMIM:52 275355

Related Diseases for Squamous Cell Carcinoma, Head and Neck

About this section

Diseases related to Squamous Cell Carcinoma, Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 146)
idRelated DiseaseScoreTop Affiliating Genes
1oral cancer11.1
2thyroid cancer11.1
3salivary gland cancer10.8
4salivary gland cancer, adult10.8
5villoglandular endometrial endometrioid adenocarcinoma10.5CCND1, PTEN, TP53
6childhood embryonal testis carcinoma10.5EGFR, PTEN, TP53
7urethral villous adenoma10.5CD44, CDKN2A, EGFR
8glioma susceptibility 210.5EGFR, PIK3CA, PTEN
9decubitus ulcer10.5CCND1, CDKN2A, STAT3
10oro-mandibular-limb hypogenesis syndrome10.5CCND1, CDKN2A, TP53
11thymus adenocarcinoma10.5EGFR, MMP2, MMP9
12adult syndrome10.5PIK3CA, PTEN, TP53
13urethral verrucous carcinoma10.5CDKN2A, PTEN, TP53
14cervical verrucous carcinoma10.4CCND1, CDKN2A, TP53
15chronic monocytic leukemia10.4CDKN2A, EGFR, TP53
16thymus squamous cell carcinoma10.4CDKN2A, EGFR, TP53
17uterine disease10.4CDKN2A, PIK3CA, TP53
18uterine cervix leukoplakia10.4CDKN2A, FHIT, TP53
19sengers syndrome10.4CDH1, CDKN2A, EGFR, PTEN
20tumor of exocrine pancreas10.4CDKN2A, EGFR, VEGFA
21senile atrophy of choroid10.4MMP2, MMP9, VEGFA
22nasopharyngeal carcinoma10.4CDKN2A, EGFR, PTEN, TP53
23secondary hyperparathyroidism of renal origin10.4CDKN2A, EGFR, TP53
24cleft palate cardiac defect ectrodactyly10.4CCND1, EGFR, TP53, VEGFA
25stenosis of lacrimal punctum10.4CCND1, CTTN, EGFR, PIK3CA
26coronary stenosis10.4PIK3CA, TP53, VEGFA
27cryoglobulinemia10.4CDKN2A, FHIT, STAT3, TP53
28pyomyositis10.4CDH1, CDKN2A, EGFR, TP53
29spastic paraplegia 110.4EGFR, PIK3CA, TP53, VEGFA
30advanced sleep phase syndrome10.4CCND1, CDH1, CDKN2A, TP53
31bronchiolitis obliterans with obstructive pulmonary disease10.4CCND1, CDH1, PIK3CA
32retroperitoneal neuroblastoma10.4CD44, PIK3CA, PTEN, TP53
33striated muscle rhabdoid tumor10.4CCND1, CDKN2A, MMP2, MMP9
34facio skeletal genital syndrome rippberger type10.4MMP2, MMP9
35reactive arthritis10.4EGFR, PIK3CA, TP53
36childhood-onset cerebral x-linked adrenoleukodystrophy10.4CDH1, CDKN2A, EGFR, TP53
37paroxysmal nocturnal hemoglobinuria10.4CDH1, CDKN2A, EGFR, TP53
38anaerobic meningitis10.4EGFR, TNFRSF10B, VEGFA
39adult oligodendroglioma10.4CDKN2A, EGFR, PTEN, TP53
40linitis plastica10.4CDH1, TP53
41placental site trophoblastic tumor10.4CDKN2A, TP53, VEGFA
42interstitial lung disease10.4CDKN2A, EGFR, PTEN, TP53, VEGFA
43immunodeficiency due to a late component of complement deficiency10.4EGFR, TP53, VEGFA
44spinal muscular atrophy with progressive myoclonic epilepsy10.4CCND1, CDKN2A, FHIT, TP53
45his bundle tachycardia10.4CCND1, EGFR, TP53
46prostatic adenoma10.4CDKN2A, EGFR, PTEN, TP53, VEGFA
47oral squamous cell carcinoma10.4CDH1, EGFR, TP53, VEGFA
48statin toxicity10.4CCND1, FHIT, MMP9, TP53
49allergic contact dermatitis10.4CDKN2A, EGFR, TP53
50adenoid squamous cell carcinoma10.4CDKN2A, MMP2, MMP9

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma, Head and Neck:



Diseases related to squamous cell carcinoma, head and neck

Symptoms & Phenotypes for Squamous Cell Carcinoma, Head and Neck

About this section

Symptoms by clinical synopsis from OMIM:

275355

Clinical features from OMIM:

275355

Human phenotypes related to Squamous Cell Carcinoma, Head and Neck:

 64
id Description HPO Frequency HPO Source Accession
1 squamous cell carcinoma64 HP:0002860

UMLS symptoms related to Squamous Cell Carcinoma, Head and Neck:


coughing, halitosis, snoring, sore throat, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00235-A9.5CCND1, CD44, CDH1, CDKN2A, ING1, MMP2

MGI Mouse Phenotypes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

41 (show all 23)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538010.2CDH1, CDKN2A, CTTN, EGFR, PIK3CA, PTEN
2MP:000536710.2CD44, CXCL14, EGFR, MMP9, PTEN, STAT3
3MP:000287310.1CCND1, CD44, CDH1, EGFR, MMP2, PTEN
4MP:00053919.9CCND1, CD44, CDKN2A, EGFR, MMP2, MMP9
5MP:00053869.9CCND1, CD44, CDKN2A, CXCL14, ING1, MMP9
6MP:00053699.9CD44, CDKN2A, EGFR, MMP2, MMP9, PIK3CA
7MP:00053909.9CCND1, CD44, CDKN2A, EGFR, MMP2, MMP9
8MP:00053899.9CCND1, CD44, CDH1, CDKN2A, CTTN, CXCL14
9MP:00053709.9CD44, CDKN2A, CXCL14, EGFR, PTEN, STAT3
10MP:00020069.8CCND1, CD44, CDH1, CDKN2A, EGFR, FHIT
11MP:00053889.8CCND1, CD44, CDKN2A, CTTN, EGFR, MMP2
12MP:00030129.8CDH1, CDKN2A, CTTN, CXCL14, EGFR, PIK3CA
13MP:00053819.8CCND1, CD44, CDH1, CDKN2A, EGFR, FHIT
14MP:00053799.8CCND1, CD44, CDH1, CDKN2A, EGFR, ING1
15MP:00053849.7CCND1, CD44, CDH1, CDKN2A, CTTN, EGFR
16MP:00053859.6CCND1, CD44, CDH1, CDKN2A, CTTN, EGFR
17MP:00107719.6CCND1, CD44, CDH1, CDKN2A, EGFR, FHIT
18MP:00053769.6CCND1, CD44, CDH1, CDKN2A, CXCL14, EGFR
19MP:00053789.5CCND1, CD44, CDH1, CDKN2A, CTTN, CXCL14
20MP:00107689.5CCND1, CD44, CDH1, CDKN2A, CTTN, CXCL14
21MP:00053979.4CCND1, CD44, CDKN2A, CTTN, CXCL14, EGFR
22MP:00053879.4CCND1, CD44, CDH1, CDKN2A, CTTN, CXCL14
23MP:00036319.3CCND1, CD44, CDKN2A, EGFR, MMP2, MMP9

Drugs & Therapeutics for Squamous Cell Carcinoma, Head and Neck

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Erbitux16 44 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
FDA Label: Erbitux
Disease/s that Drug Treats:Colorectal Cancer
Indications and Usage:16 Erbitux® is an epidermal growth factor receptor (EGFR) antagonist indicatedfor treatment of:Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the headand neck in combination with radiation therapy. (1.1, 14.1) Recurrent locoregional disease or metastatic squamous cell carcinomaof the head and neck in combination with platinum-based therapy with5-FU. (1.1, 14.1) Recurrent or metastatic squamous cell carcinoma of the head and neckprogressing after platinum-based therapy. (1.1, 14.1)Colorectal CancerK-Ras wild-type, EGFR-expressing, metastatic colorectal cancer asdetermined by FDA-approved tests in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory toirinotecan-based chemotherapy, as a single agent in patients who have failed oxaliplatin- andirinotecan-based chemotherapy or who are intolerant to irinotecan.(1.2, 5.7, 12.1, 14.2)Limitation of Use: Erbitux is not indicated for treatment of Ras-mutantcolorectal cancer. (5.7, 14.2)
DrugBank Targets:14 1. Epidermal growth factor receptor;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:16 
Target: binding of epidermal growth factor (EGF) and other ligands to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1)
Action: inhibitor
FDA: The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembraneglycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR,HER2, HER3, and HER4. The EGFR is constitutively expressed in many normal epithelialtissues, including the skin and hair follicle. Expression of EGFR is also detected in many humancancers including those of the head and neck, colon, and rectum. Cetuximab binds specifically to the EGFR on both normal and tumor cells, and competitivelyinhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforminggrowth factor-alpha. In vitro assays and in vivo animal studies have shown that binding ofcetuximab to the EGFR blocks phosphorylation and activation of receptor-associated kinases,resulting in inhibition of cell growth, induction of apoptosis, and decreased matrixmetalloproteinase and vascular endothelial growth factor production. Signal transduction throughthe EGFR results in activation of wild-type Ras proteins, but in cells with activating Ras somaticmutations, the resulting mutant Ras proteins are continuously active regardless of EGFRregulation.In vitro, cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC) against certainhuman tumor types. In vitro assays and in vivo animal studies have shown that cetuximabinhibits the growth and survival of tumor cells that express the EGFR. No anti-tumor effects ofcetuximab were observed in human tumor xenografts lacking EGFR expression. The addition ofcetuximab to radiation therapy or irinotecan in human tumor xenograft models in mice resultedin an increase in anti-tumor effects compared to radiation therapy or chemotherapy alone.
2
Ethyol16 AMIFOSTINE Alza December 8, 1995
FDA Label: Ethyol
Disease/s that Drug Treats:ovarian cancer
Indications and Usage:16 ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated withrepeated administration of cisplatin in patients with advanced ovarian cancer.ETHYOL is indicated to reduce the incidence of moderate to severe xerostomia in patientsundergoing post-operative radiation treatment for head and neck cancer, where the radiationport includes a substantial portion of the parotid glands (see Clinical Studies).For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin basedchemotherapy regimens or radiation therapy is altered by ETHYOL. There are at present only limiteddata on the effects of ETHYOL on the efficacy of chemotherapy or radiotherapy in other settings.ETHYOL should not be administered to patients in other settings where chemotherapy can produce asignificant survival benefit or cure, or in patients receiving definitive radiotherapy, except in thecontext of a clinical study (see WARNINGS).
DrugBank Targets:14 1. Ectonucleotide pyrophosphatase/phosphodiesterase family member 1;2. Alkaline phosphatase, placental-like
Mechanism of Action:16 
Target: -
Action: -
FDA: -
3
Taxotere16 44 DOCETAXEL Rhone Poulenc Rorer May 1996
FDA Label: Taxotere
Disease/s that Drug Treats:breast cancer
Indications and Usage:16 TAXOTERE is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BCafter chemotherapy failure; and with doxorubicin andcyclophosphamide as adjuvant treatment of operable node-positive BC(1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locallyadvanced or metastatic NSCLC after platinum therapy failure; andwith cisplatin for unresectable, locally advanced or metastaticuntreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone inandrogen independent (hormone refractory) metastatic prostate cancer(1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil foruntreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN):with cisplatin and fluorouracil for induction treatment of locallyadvanced SCCHN (1.5)
DrugBank Targets:14 1. Tubulin beta-1 chain;2. Apoptosis regulator Bcl-2;3. Microtubule-associated protein 2;4. Microtubule-associated protein 4;5. Microtubule-associated protein tau;6. Nuclear receptor subfamily 1 group I member 2
Mechanism of Action:16 
Target: free tubulin
Action: promoter of assembly
FDA: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that isessential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes theassembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. Thisleads to the production of microtubule bundles without normal function and to the stabilization ofmicrotubules, which results in the inhibition of mitosis in cells. Docetaxel’s binding to microtubulesdoes not alter the number of protofilaments in the bound microtubules, a feature which differs from mostspindle poisons currently in clinical use.

Drugs for Squamous Cell Carcinoma, Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 493)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FluorouracilapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
2
EthanolapprovedPhase 4, Phase 1213764-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
3
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
4
CetuximabapprovedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1752205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
5
CevimelineapprovedPhase 4, Phase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline [INN]
 
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
6
Gefitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1361184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
7Titanium dioxideapprovedPhase 43813463-67-7
8
Morphineapproved, investigationalPhase 4100757-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
9
Fentanylapproved, illicit, investigational, vet_approvedPhase 4821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
10
PetrolatumapprovedPhase 4938009-03-8
Synonyms:
Multi-hydrocarbon
Paraffinum album
Paraffinum flavum
Petrolatum base
Petrolatum, white
 
Petrolatum,amber
Petrolatum,white
Petroleum jelly
Soft paraffin
White petrolatum
White, soft paraffin
Yellow soft paraffin
11
Docetaxelapproved, investigational, Approved May 1996Phase 4, Phase 2, Phase 3, Phase 1, Early Phase 11967114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
12Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 123689
13Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15806
14Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 110729
15Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 18192
16Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 110150
17AnalgesicsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 111733
18Cholinergic AgentsPhase 4, Phase 33992
19Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Early Phase 118340
20Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14962
21Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 17180
22Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 111226
23Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 14827
24AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112054
25Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17361
26Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 113086
27Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15657
28Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13689
29Central Nervous System DepressantsPhase 4, Phase 2, Early Phase 113403
30AnestheticsPhase 4, Phase 3, Phase 29596
31MitomycinsPhase 4, Phase 3, Phase 2240
32NarcoticsPhase 4, Phase 23646
33Anti-Allergic AgentsPhase 4, Phase 21522
34Adjuvants, AnesthesiaPhase 41674
35mometasone furoatePhase 417883919-23-7
36Anesthetics, IntravenousPhase 42538
37Anesthetics, GeneralPhase 42934
38Analgesics, OpioidPhase 4, Phase 23238
39arginineNutraceuticalPhase 4, Phase 2, Phase 1425
40Omega 3 Fatty AcidNutraceuticalPhase 4, Phase 2, Phase 11018
41
CitalopramapprovedPhase 351259729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
42
Aspirinapproved, vet_approvedPhase 3, Phase 2115250-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalicylsäure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide acetylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
Entericin
Enterophen
 
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
acide 2-(acétyloxy)benzoïque
acide acétylsalicylique
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
salicylic acid acetate
ácido acetilsalicílico
43
Imiquimodapproved, investigationalPhase 2, Phase 314099011-02-657469
Synonyms:
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC-529
AC1L1N2I
AC1Q4YO9
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
BIDD:GT0859
Beselna
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
 
I06-0624
I06-2289
I0747
I5159_SIGMA
IMIQUIMOD
Imiquimod
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MTD-39
MolPort-002-507-845
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S-26308
S1211_Selleck
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
ZINC19632912
Zartra
Zyclara
imiquimod
44
AldesleukinapprovedPhase 3, Phase 2, Phase 140585898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
45
Irinotecanapproved, investigationalPhase 3, Phase 2, Phase 1112397682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
46
Cyclophosphamideapproved, investigationalPhase 3, Phase 2, Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
47
GemcitabineapprovedPhase 3, Phase 2, Phase 1201895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
48
MethotrexateapprovedPhase 3, Phase 2, Phase 115511959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
49
Oxaliplatinapproved, investigationalPhase 2, Phase 3, Phase 1146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
50
Amifostineapproved, investigationalPhase 3, Phase 1, Phase 28120537-88-62141
Synonyms:
Amifostina
Amifostine
Amifostine Ethiofos
Amifostinum
Aminopropylaminoethyl Thiophosphate
 
Apaetp
Ethiofos
Ethyol
Gammaphos
SAPEP
WR-1065

Interventional clinical trials:

(show top 50)    (show all 1420)
idNameStatusNCT IDPhase
1Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)Unknown statusNCT01553032Phase 4
2A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous CarcinomaUnknown statusNCT00642239Phase 4
3Post-marketing Surveillance Study of Docetaxel-Based ChemotherapyCompletedNCT02972216Phase 4
4Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx CarcinomaCompletedNCT00772681Phase 4
5Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced XerostomiaCompletedNCT00466388Phase 4
6Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer PatientsCompletedNCT02622880Phase 4
7A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer PatientsCompletedNCT01283906Phase 4
8Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and NeckRecruitingNCT02015650Phase 4
9Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' PatientsRecruitingNCT02495064Phase 4
10Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional GastrostomyRecruitingNCT02869321Phase 4
11An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and NeckActive, not recruitingNCT00684385Phase 4
12Stereotactic Body Radiotherapy for Head and Neck TumorsActive, not recruitingNCT01344356Phase 4
13S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck CancerUnknown statusNCT00336947Phase 3
14Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck CancerUnknown statusNCT00002659Phase 3
15Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving MethotrexateUnknown statusNCT00041613Phase 3
16Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy AloneUnknown statusNCT00041626Phase 3
17Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.Unknown statusNCT01124409Phase 3
18Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer TreatmentUnknown statusNCT00935675Phase 3
19Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth CancerUnknown statusNCT00002747Phase 3
20Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or OropharynxUnknown statusNCT00002702Phase 3
21Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or HypopharynxUnknown statusNCT00003627Phase 3
22Topical Imiquimod for Bowen's Disease of the Head and NeckUnknown statusNCT00384124Phase 2, Phase 3
23Oral Cancer Adjuvant Therapy (OCAT) TrialUnknown statusNCT00193843Phase 3
24PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck CancerUnknown statusNCT00720070Phase 3
25Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the NasopharynxUnknown statusNCT00003637Phase 3
26Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal CancerUnknown statusNCT01434394Phase 2, Phase 3
27Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced XerostomiaUnknown statusNCT00081029Phase 3
28Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea PolyphenolsUnknown statusNCT01496521Phase 3
29Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After EsophagectomyUnknown statusNCT01402180Phase 2, Phase 3
30Elective or Prophylactic Nodal Irradiation for Esophageal CancerUnknown statusNCT01551589Phase 3
31Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 TrialUnknown statusNCT02319187Phase 3
32Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIALUnknown statusNCT01039298Phase 3
33Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the EsophagusUnknown statusNCT00002884Phase 3
34Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal CancerUnknown statusNCT00509561Phase 2, Phase 3
35Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and NeckCompletedNCT00442455Phase 3
36Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese SubjectsCompletedNCT01012258Phase 3
37Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)CompletedNCT00206219Phase 3
38Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT01086826Phase 3
39A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and NeckCompletedNCT01177956Phase 3
40Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)CompletedNCT00122460Phase 3
41Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00771641Phase 3
42DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCCCompletedNCT00496652Phase 3
43Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT00401323Phase 2, Phase 3
44Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00460265Phase 3
45Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck CancersCompletedNCT01166542Phase 3
46Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck CancerCompletedNCT00003592Phase 3
47Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During SurgeryCompletedNCT00002670Phase 3
48Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00003888Phase 3
49Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck CancerCompletedNCT00006481Phase 3
50Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After SurgeryCompletedNCT00424255Phase 3

Search NIH Clinical Center for Squamous Cell Carcinoma, Head and Neck


Cochrane evidence based reviews: carcinoma, squamous cell of head and neck

Genetic Tests for Squamous Cell Carcinoma, Head and Neck

About this section

Genetic tests related to Squamous Cell Carcinoma, Head and Neck:

id Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of the Head and Neck27

Anatomical Context for Squamous Cell Carcinoma, Head and Neck

About this section

MalaCards organs/tissues related to Squamous Cell Carcinoma, Head and Neck:

36
Skin, Testes, Salivary gland, Lymph node, Breast, Endothelial, T cells

Publications for Squamous Cell Carcinoma, Head and Neck

About this section

Variations for Squamous Cell Carcinoma, Head and Neck

About this section

UniProtKB/Swiss-Prot genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

70
id Symbol AA change Variation ID SNP ID
1ING1p.Ala335AspVAR_017420
2ING1p.Cys358SerVAR_017421
3ING1p.Asn359SerVAR_017422
4ING3p.Asp20GlyVAR_021263
5PTENp.Ala121GlyVAR_018103rs121909237

Clinvar genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

5 (show all 307)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_ 000546.5(TP53): c.742C> T (p.Arg248Trp)SNVPathogenic/ Likely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
2TP53NM_ 000546.5(TP53): c.733G> T (p.Gly245Cys)SNVPathogenic/ Likely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
3TP53NM_ 000546.5(TP53): c.725G> A (p.Cys242Tyr)SNVPathogenic/ Likely pathogenicrs121912655GRCh37Chr 17, 7577556: 7577556
4TP53NM_ 000546.5(TP53): c.734G> A (p.Gly245Asp)SNVPathogenic/ Likely pathogenicrs121912656GRCh37Chr 17, 7577547: 7577547
5TP53NM_ 000546.5(TP53): c.743G> A (p.Arg248Gln)SNVPathogenic/ Likely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
6TP53NM_ 000546.5(TP53): c.722C> T (p.Ser241Phe)SNVPathogenic/ Likely pathogenicrs28934573GRCh37Chr 17, 7577559: 7577559
7TP53NM_ 000546.5(TP53): c.733G> A (p.Gly245Ser)SNVPathogenic/ Likely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
8TP53NM_ 000546.5(TP53): c.818G> A (p.Arg273His)SNVPathogenic/ Likely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
9TP53NM_ 000546.5(TP53): c.451C> A (p.Pro151Thr)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
10TP53NM_ 000546.5(TP53): c.451C> T (p.Pro151Ser)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
11TP53NM_ 000546.5(TP53): c.659A> C (p.Tyr220Ser)SNVPathogenic/ Likely pathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
12HRASNM_ 005343.3(HRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
13HRASNM_ 005343.3(HRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs104894230GRCh37Chr 11, 534288: 534288
14HRASNM_ 005343.3(HRAS): c.37G> T (p.Gly13Cys)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
15HRASNM_ 005343.3(HRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
16EGFRNM_ 005228.4(EGFR): c.2327G> A (p.Arg776His)SNVdrug responsers483352806GRCh37Chr 7, 55249029: 55249029
17EGFRNM_ 005228.4(EGFR): c.2471G> A (p.Gly824Asp)SNVdrug responsers483352808GRCh38Chr 7, 55191720: 55191720
18EGFRNM_ 005228.4(EGFR): c.2188C> G (p.Leu730Val)SNVdrug responsers121913434GRCh37Chr 7, 55242418: 55242418
19EGFRNM_ 005228.4(EGFR): c.2393T> A (p.Leu798His)SNVdrug responsers483352807GRCh38Chr 7, 55181402: 55181402
20EGFRNM_ 005228.4(EGFR): c.2176G> A (p.Val726Met)SNVdrug responsers483352805GRCh37Chr 7, 55241728: 55241728
21TP53NM_ 000546.5(TP53): c.488A> G (p.Tyr163Cys)SNVPathogenic/ Likely pathogenicrs148924904GRCh37Chr 17, 7578442: 7578442
22TP53NM_ 000546.5(TP53): c.535C> T (p.His179Tyr)SNVPathogenic/ Likely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
23TP53NM_ 000546.5(TP53): c.580C> T (p.Leu194Phe)SNVPathogenic/ Likely pathogenicrs587780071GRCh37Chr 17, 7578269: 7578269
24TP53NM_ 000546.5(TP53): c.659A> G (p.Tyr220Cys)SNVPathogenic/ Likely pathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
25TP53NM_ 000546.5(TP53): c.701A> G (p.Tyr234Cys)SNVPathogenic/ Likely pathogenicrs587780073GRCh37Chr 17, 7577580: 7577580
26TP53NM_ 000546.5(TP53): c.638G> A (p.Arg213Gln)SNVPathogenic/ Likely pathogenicrs587778720GRCh38Chr 17, 7674893: 7674893
27PIK3CANM_ 006218.3(PIK3CA): c.3140A> G (p.His1047Arg)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
28PIK3CANM_ 006218.3(PIK3CA): c.3140A> T (p.His1047Leu)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
29PIK3CANM_ 006218.3(PIK3CA): c.1636C> G (p.Gln546Glu)SNVPathogenic/ Likely pathogenicrs121913286GRCh37Chr 3, 178936094: 178936094
30PIK3CANM_ 006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
31PIK3CANM_ 006218.3(PIK3CA): c.1634A> G (p.Glu545Gly)SNVPathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
32PIK3CANM_ 006218.3(PIK3CA): c.1636C> A (p.Gln546Lys)SNVPathogenic/ Likely pathogenicrs121913286GRCh37Chr 3, 178936094: 178936094
33BRAFNM_ 004333.4(BRAF): c.1799T> A (p.Val600Glu)SNVPathogenic/ Likely pathogenicrs113488022GRCh37Chr 7, 140453136: 140453136
34BRAFNM_ 004333.4(BRAF): c.1397G> T (p.Gly466Val)SNVPathogenic/ Likely pathogenicrs121913351GRCh37Chr 7, 140481411: 140481411
35BRAFNM_ 004333.4(BRAF): c.1781A> G (p.Asp594Gly)SNVPathogenic/ Likely pathogenicrs121913338GRCh37Chr 7, 140453154: 140453154
36AKT1NM_ 005163.2(AKT1): c.49G> A (p.Glu17Lys)SNVPathogenic/ Likely pathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
37TP53NM_ 000546.5(TP53): c.422G> A (p.Cys141Tyr)SNVPathogenic/ Likely pathogenicrs587781288GRCh37Chr 17, 7578508: 7578508
38TP53NM_ 000546.5(TP53): c.844C> G (p.Arg282Gly)SNVPathogenic/ Likely pathogenicrs28934574GRCh37Chr 17, 7577094: 7577094
39TP53NM_ 000546.5(TP53): c.842A> G (p.Asp281Gly)SNVPathogenic/ Likely pathogenicrs587781525GRCh37Chr 17, 7577096: 7577096
40PTENNM_ 000314.6(PTEN): c.389G> C (p.Arg130Pro)SNVLikely pathogenicrs121909229GRCh37Chr 10, 89692905: 89692905
41TP53NM_ 000546.5(TP53): c.706T> G (p.Tyr236Asp)SNVPathogenic/ Likely pathogenicrs587782289GRCh37Chr 17, 7577575: 7577575
42IDH2NM_ 002168.3(IDH2): c.419G> A (p.Arg140Gln)SNVPathogenic/ Likely pathogenicrs121913502GRCh37Chr 15, 90631934: 90631934
43PIK3CANM_ 006218.3(PIK3CA): c.353G> A (p.Gly118Asp)SNVPathogenic/ Likely pathogenicrs587777790GRCh38Chr 3, 179199690: 179199690
44PIK3CANM_ 006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)SNV, HaplotypePathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
45GNASNM_ 000516.5(GNAS): c.601C> T (p.Arg201Cys)SNVPathogenic/ Likely pathogenicrs11554273GRCh37Chr 20, 57484420: 57484420
46GNASNM_ 000516.5(GNAS): c.602G> A (p.Arg201His)SNVPathogenic/ Likely pathogenicrs121913495GRCh37Chr 20, 57484421: 57484421
47FGFR3NM_ 000142.4(FGFR3): c.742C> T (p.Arg248Cys)SNVPathogenic/ Likely pathogenicrs121913482GRCh37Chr 4, 1803564: 1803564
48FGFR3NM_ 000142.4(FGFR3): c.746C> G (p.Ser249Cys)SNVPathogenic/ Likely pathogenicrs121913483GRCh37Chr 4, 1803568: 1803568
49CTNNB1NM_ 001904.3(CTNNB1): c.101G> A (p.Gly34Glu)SNVPathogenic/ Likely pathogenicrs28931589GRCh37Chr 3, 41266104: 41266104
50TP53NM_ 000546.5(TP53): c.722C> G (p.Ser241Cys)SNVLikely pathogenicrs28934573GRCh38Chr 17, 7674241: 7674241
51PIK3CANM_ 006218.3(PIK3CA): c.3129G> A (p.Met1043Ile)SNVPathogenic/ Likely pathogenicrs121913283GRCh37Chr 3, 178952074: 178952074
52HRASNM_ 005343.3(HRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs104894226GRCh38Chr 11, 534285: 534285
53TP53NM_ 000546.5(TP53): c.842A> T (p.Asp281Val)SNVPathogenic/ Likely pathogenicrs587781525GRCh38Chr 17, 7673778: 7673778
54TP53NM_ 000546.5(TP53): c.856G> A (p.Glu286Lys)SNVPathogenic/ Likely pathogenicrs786201059GRCh37Chr 17, 7577082: 7577082
55TP53NM_ 000546.5(TP53): c.578A> T (p.His193Leu)SNVLikely pathogenicrs786201838GRCh37Chr 17, 7578271: 7578271
56TP53NM_ 000546.5(TP53): c.487T> G (p.Tyr163Asp)SNVLikely pathogenicrs786203436GRCh37Chr 17, 7578443: 7578443
57GNASNM_ 000516.5(GNAS): c.602G> T (p.Arg201Leu)SNVPathogenic/ Likely pathogenicrs121913495GRCh37Chr 20, 57484421: 57484421
58TP53NM_ 000546.5(TP53): c.824G> A (p.Cys275Tyr)SNVPathogenic/ Likely pathogenicrs863224451GRCh38Chr 17, 7673796: 7673796
59TP53NM_ 000546.5(TP53): c.584T> C (p.Ile195Thr)SNVPathogenic/ Likely pathogenicrs760043106GRCh38Chr 17, 7674947: 7674947
60PIK3CANM_ 006218.3(PIK3CA): c.1635G> T (p.Glu545Asp)SNVPathogenic/ Likely pathogenicrs121913275GRCh37Chr 3, 178936093: 178936093
61TP53NM_ 000546.5(TP53): c.743G> T (p.Arg248Leu)SNVLikely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
62TP53NM_ 000546.5(TP53): c.577C> T (p.His193Tyr)SNVLikely pathogenicrs876658468GRCh37Chr 17, 7578272: 7578272
63TP53NM_ 000546.5(TP53): c.818G> C (p.Arg273Pro)SNVLikely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
64TP53NM_ 000546.5(TP53): c.587G> C (p.Arg196Pro)SNVLikely pathogenicrs483352697GRCh37Chr 17, 7578262: 7578262
65TP53NM_ 000546.5(TP53): c.638G> C (p.Arg213Pro)SNVLikely pathogenicrs587778720GRCh37Chr 17, 7578211: 7578211
66TP53NM_ 000546.5(TP53): c.833C> T (p.Pro278Leu)SNVPathogenic/ Likely pathogenicrs876659802GRCh37Chr 17, 7577105: 7577105
67TP53NM_ 000546.5(TP53): c.715A> G (p.Asn239Asp)SNVLikely pathogenicrs876660807GRCh37Chr 17, 7577566: 7577566
68TP53NM_ 000546.5(TP53): c.743G> C (p.Arg248Pro)SNVLikely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
69SMAD4NM_ 005359.5(SMAD4): c.1081C> G (p.Arg361Gly)SNVPathogenic/ Likely pathogenicrs80338963GRCh37Chr 18, 48591918: 48591918
70SMAD4NM_ 005359.5(SMAD4): c.1082G> A (p.Arg361His)SNVPathogenic/ Likely pathogenicrs377767347GRCh37Chr 18, 48591919: 48591919
71TP53NM_ 000546.5(TP53): c.734G> C (p.Gly245Ala)SNVLikely pathogenicrs121912656GRCh37Chr 17, 7577547: 7577547
72PIK3CANM_ 006218.3(PIK3CA): c.1624G> A (p.Glu542Lys)SNVPathogenic/ Likely pathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
73HRASNM_ 005343.3(HRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
74TP53NM_ 000546.5(TP53): c.731G> A (p.Gly244Asp)SNVLikely pathogenicrs985033810GRCh37Chr 17, 7577550: 7577550
75PIK3CANM_ 006218.3(PIK3CA): c.1633G> C (p.Glu545Gln)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
76PIK3CANM_ 006218.3(PIK3CA): c.1637A> C (p.Gln546Pro)SNVPathogenic/ Likely pathogenicrs397517201GRCh37Chr 3, 178936095: 178936095
77PIK3CANM_ 006218.3(PIK3CA): c.1637A> T (p.Gln546Leu)SNVPathogenic/ Likely pathogenicrs397517201GRCh37Chr 3, 178936095: 178936095
78BRAFNM_ 004333.4(BRAF): c.1780G> C (p.Asp594His)SNVPathogenic/ Likely pathogenicrs397516896GRCh37Chr 7, 140453155: 140453155
79PTENNM_ 000314.6(PTEN): c.388C> G (p.Arg130Gly)SNVPathogenic/ Likely pathogenicrs121909224GRCh37Chr 10, 89692904: 89692904
80IDH2NM_ 002168.3(IDH2): c.419G> T (p.Arg140Leu)SNVPathogenic/ Likely pathogenicrs121913502GRCh37Chr 15, 90631934: 90631934
81IDH2NM_ 002168.3(IDH2): c.418C> T (p.Arg140Trp)SNVPathogenic/ Likely pathogenicrs267606870GRCh37Chr 15, 90631935: 90631935
82TP53NM_ 001126112.2(TP53): c.746G> C (p.Arg249Thr)SNVLikely pathogenicrs587782329GRCh37Chr 17, 7577535: 7577535
83TP53NM_ 001126112.2(TP53): c.518T> G (p.Val173Gly)SNVLikely pathogenicrs1057519747GRCh37Chr 17, 7578412: 7578412
84TP53NM_ 001126113.2(TP53): c.518T> C (p.Val173Ala)SNVLikely pathogenicrs1057519747GRCh37Chr 17, 7578412: 7578412
85U2AF1NM_ 006758.2(U2AF1): c.101C> T (p.Ser34Phe)SNVLikely pathogenicrs371769427GRCh37Chr 21, 44524456: 44524456
86U2AF1NM_ 001025203.1(U2AF1): c.101C> A (p.Ser34Tyr)SNVLikely pathogenicrs371769427GRCh37Chr 21, 44524456: 44524456
87HRAS; LRRC56NM_ 005343.3(HRAS): c.182A> T (p.Gln61Leu)SNVLikely pathogenicrs121913233GRCh37Chr 11, 533874: 533874
88PIK3CANM_ 006218.3(PIK3CA): c.263G> A (p.Arg88Gln)SNVLikely pathogenicrs121913287GRCh37Chr 3, 178916876: 178916876
89PIK3CANM_ 006218.3(PIK3CA): c.1035T> A (p.Asn345Lys)SNVLikely pathogenicrs121913284GRCh37Chr 3, 178921553: 178921553
90BRAFNM_ 004333.4(BRAF): c.1397G> A (p.Gly466Glu)SNVLikely pathogenicrs121913351GRCh37Chr 7, 140481411: 140481411
91EGFRNM_ 005228.4(EGFR): c.2234A> G (p.Lys745Arg)SNVLikely pathogenicrs121913433GRCh37Chr 7, 55242464: 55242464
92MAP2K1NM_ 002755.3(MAP2K1): c.171G> C (p.Lys57Asn)SNVLikely pathogenicrs869025608GRCh37Chr 15, 66727455: 66727455
93ERBB2NM_ 001289938.1(ERBB2): c.839C> A (p.Ser280Tyr)SNVLikely pathogenicrs1057519816GRCh37Chr 17, 37868208: 37868208
94ERBB2NM_ 001289938.1(ERBB2): c.839C> T (p.Ser280Phe)SNVLikely pathogenicrs1057519816GRCh37Chr 17, 37868208: 37868208
95EGFRNM_ 005228.4(EGFR): c.866C> T (p.Ala289Val)SNVLikely pathogenicrs149840192GRCh37Chr 7, 55221822: 55221822
96CTNNB1NM_ 001904.3(CTNNB1): c.100G> C (p.Gly34Arg)SNVLikely pathogenicrs121913399GRCh37Chr 3, 41266103: 41266103
97PIK3CANM_ 006218.3(PIK3CA): c.1624G> C (p.Glu542Gln)SNVLikely pathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
98BRAFNM_ 004333.4(BRAF): c.1397G> C (p.Gly466Ala)SNVLikely pathogenicrs121913351GRCh37Chr 7, 140481411: 140481411
99CDKN2ANM_ 058195.3(CDKN2A): c.290C> T (p.Ala97Val)SNVLikely pathogenicrs121913385GRCh37Chr 9, 21971111: 21971111
100HRAS; LRRC56NM_ 005343.3(HRAS): c.183G> T (p.Gln61His)SNVLikely pathogenicrs121913496GRCh37Chr 11, 533873: 533873
101HRAS; LRRC56NM_ 005343.3(HRAS): c.37G> A (p.Gly13Ser)SNVLikely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
102RAC1NM_ 018890.3(RAC1): c.85C> T (p.Pro29Ser)SNVLikely pathogenicrs1057519874GRCh37Chr 7, 6426892: 6426892
103B2MNM_ 004048.2(B2M): c.3G> A (p.Met1Ile)SNVLikely pathogenicrs1057519877GRCh37Chr 15, 45003747: 45003747
104B2MNM_ 004048.2(B2M): c.1A> G (p.Met1Val)SNVLikely pathogenicrs1023835002GRCh37Chr 15, 45003745: 45003745
105B2MNM_ 004048.2(B2M): c.1A> T (p.Met1Leu)SNVLikely pathogenicrs1023835002GRCh37Chr 15, 45003745: 45003745
106B2MNM_ 004048.2(B2M): c.2T> C (p.Met1Thr)SNVLikely pathogenicrs1057519879GRCh37Chr 15, 45003746: 45003746
107B2MNM_ 004048.2(B2M): c.2T> G (p.Met1Arg)SNVLikely pathogenicrs1057519879GRCh37Chr 15, 45003746: 45003746
108CDKN2ANM_ 058195.3(CDKN2A): c.291A> G (p.Ala97=)SNVLikely pathogenicrs1057519881GRCh38Chr 9, 21971111: 21971111
109CDKN2ANM_ 058195.3(CDKN2A): c.290C> G (p.Ala97Gly)SNVLikely pathogenicrs121913385GRCh37Chr 9, 21971111: 21971111
110CDKN2ANM_ 000077.4(CDKN2A): c.249C> G (p.His83Gln)SNVLikely pathogenicrs34968276GRCh37Chr 9, 21971109: 21971109
111CDKN2ANM_ 058195.3(CDKN2A): c.383C> A (p.Ala128Asp)SNVLikely pathogenicrs104894104GRCh37Chr 9, 21971018: 21971018
112CDKN2ANM_ 058195.3(CDKN2A): c.384C> A (p.Ala128=)SNVLikely pathogenicrs121913386GRCh37Chr 9, 21971017: 21971017
113CDKN2ANM_ 000077.4(CDKN2A): c.150G> T (p.Gln50His)SNVLikely pathogenicrs1057519882GRCh37Chr 9, 21974677: 21974677
114CDKN2ANM_ 000077.4(CDKN2A): c.239G> A (p.Arg80Gln)SNVLikely pathogenicrs1057519883GRCh38Chr 9, 21971120: 21971120
115CREBBPNM_ 004380.2(CREBBP): c.4337G> T (p.Arg1446Leu)SNVLikely pathogenicrs1057519884GRCh37Chr 16, 3788617: 3788617
116CREBBPNM_ 004380.2(CREBBP): c.4337G> A (p.Arg1446His)SNVLikely pathogenicrs1057519884GRCh37Chr 16, 3788617: 3788617
117CREBBPNM_ 004380.2(CREBBP): c.4336C> G (p.Arg1446Gly)SNVLikely pathogenicrs398124146GRCh37Chr 16, 3788618: 3788618
118CTNNB1NM_ 001904.3(CTNNB1): c.101G> C (p.Gly34Ala)SNVLikely pathogenicrs28931589GRCh37Chr 3, 41266104: 41266104
119EGFRNM_ 005228.4(EGFR): c.865G> A (p.Ala289Thr)SNVLikely pathogenicrs769696078GRCh37Chr 7, 55221821: 55221821
120EGFRNM_ 005228.4(EGFR): c.866C> A (p.Ala289Asp)SNVLikely pathogenicrs149840192GRCh37Chr 7, 55221822: 55221822
121EGFRNM_ 005228.4(EGFR): c.865_ 866delGCinsAA (p.Ala289Asn)indelLikely pathogenicrs1057519887GRCh37Chr 7, 55221821: 55221822
122EGFRNM_ 005228.4(EGFR): c.865_ 866delGCinsAT (p.Ala289Ile)indelLikely pathogenicrs1057519887GRCh37Chr 7, 55221821: 55221822
123EP300NM_ 001429.3(EP300): c.4195G> A (p.Asp1399Asn)SNVLikely pathogenicrs1057519889GRCh37Chr 22, 41565529: 41565529
124EP300NM_ 001429.3(EP300): c.4195G> T (p.Asp1399Tyr)SNVLikely pathogenicrs1057519889GRCh37Chr 22, 41565529: 41565529
125FBXW7NM_ 033632.3(FBXW7): c.1393C> T (p.Arg465Cys)SNVLikely pathogenicrs867384286GRCh37Chr 4, 153249385: 153249385
126FBXW7NM_ 033632.3(FBXW7): c.1394G> A (p.Arg465His)SNVLikely pathogenicrs1057519895GRCh37Chr 4, 153249384: 153249384
127FBXW7NM_ 033632.3(FBXW7): c.1394G> C (p.Arg465Pro)SNVLikely pathogenicrs1057519895GRCh37Chr 4, 153249384: 153249384
128FBXW7NM_ 033632.3(FBXW7): c.1394G> T (p.Arg465Leu)SNVLikely pathogenicrs1057519895GRCh37Chr 4, 153249384: 153249384
129FBXW7NM_ 033632.3(FBXW7): c.1393C> G (p.Arg465Gly)SNVLikely pathogenicrs867384286GRCh37Chr 4, 153249385: 153249385
130FBXW7NM_ 033632.3(FBXW7): c.1436G> A (p.Arg479Gln)SNVLikely pathogenicrs866987936GRCh38Chr 4, 152326214: 152326214
131FBXW7NM_ 033632.3(FBXW7): c.1436G> C (p.Arg479Pro)SNVLikely pathogenicrs866987936GRCh37Chr 4, 153247366: 153247366
132FBXW7NM_ 033632.3(FBXW7): c.1436G> T (p.Arg479Leu)SNVLikely pathogenicrs866987936GRCh37Chr 4, 153247366: 153247366
133FBXW7NM_ 033632.3(FBXW7): c.1435C> G (p.Arg479Gly)SNVLikely pathogenicrs747241612GRCh37Chr 4, 153247367: 153247367
134FBXW7NM_ 033632.3(FBXW7): c.1513C> G (p.Arg505Gly)SNVLikely pathogenicrs149680468GRCh37Chr 4, 153247289: 153247289
135FBXW7NM_ 033632.3(FBXW7): c.1514G> T (p.Arg505Leu)SNVLikely pathogenicrs1057519896GRCh37Chr 4, 153247288: 153247288
136FBXW7NM_ 033632.3(FBXW7): c.1514G> A (p.Arg505His)SNVLikely pathogenicrs1057519896GRCh37Chr 4, 153247288: 153247288
137FBXW7NM_ 033632.3(FBXW7): c.1513C> A (p.Arg505Ser)SNVLikely pathogenicrs149680468GRCh38Chr 4, 152326137: 152326137
138FBXW7NM_ 033632.3(FBXW7): c.1973G> A (p.Arg658Gln)SNVLikely pathogenicrs759610249GRCh37Chr 4, 153244184: 153244184
139HIST1H3INM_ 003533.2(HIST1H3I): c.83A> T (p.Lys28Met)SNVLikely pathogenicrs1057519904GRCh37Chr 6, 27840011: 27840011
140HIST1H3INM_ 003533.2(HIST1H3I): c.82A> G (p.Lys28Glu)SNVLikely pathogenicrs1057519905GRCh37Chr 6, 27840012: 27840012
141MAP2K1NM_ 002755.3(MAP2K1): c.170A> C (p.Lys57Thr)SNVLikely pathogenicrs1057519909GRCh37Chr 15, 66727454: 66727454
142MAP2K2NM_ 030662.3(MAP2K2): c.171T> G (p.Phe57Leu)SNVLikely pathogenicrs1057519910GRCh37Chr 19, 4117549: 4117549
143MAPK1NM_ 002745.4(MAPK1): c.964G> A (p.Glu322Lys)SNVLikely pathogenicrs1057519911GRCh37Chr 22, 22127164: 22127164
144NFE2L2NM_ 001313903.1(NFE2L2): c.85G> C (p.Asp29His)SNVLikely pathogenicrs1057519920GRCh38Chr 2, 177234232: 177234232
145NFE2L2NM_ 001145412.3(NFE2L2): c.37G> T (p.Asp13Tyr)SNVLikely pathogenicrs1057519920GRCh37Chr 2, 178098960: 178098960
146NFE2L2NM_ 001313903.1(NFE2L2): c.85G> A (p.Asp29Asn)SNVLikely pathogenicrs1057519920GRCh37Chr 2, 178098960: 178098960
147NFE2L2NM_ 001145412.3(NFE2L2): c.38A> G (p.Asp13Gly)SNVLikely pathogenicrs1057519921GRCh37Chr 2, 178098959: 178098959
148NFE2L2NM_ 001145413.3(NFE2L2): c.187G> C (p.Glu63Gln)SNVLikely pathogenicrs1057519922GRCh37Chr 2, 178098810: 178098810
149NFE2L2NM_ 001313904.1(NFE2L2): c.6G> A (p.Lys2=)SNVLikely pathogenicrs1057519922GRCh37Chr 2, 178098810: 178098810
150NFE2L2NM_ 001145413.3(NFE2L2): c.188A> T (p.Glu63Val)SNVLikely pathogenicrs1057519923GRCh37Chr 2, 178098809: 178098809
151NFE2L2NM_ 001313902.1(NFE2L2): c.237G> T (p.Glu79Asp)SNVLikely pathogenicrs1057519924GRCh37Chr 2, 178098808: 178098808
152PIK3CANM_ 006218.3(PIK3CA): c.1357G> A (p.Glu453Lys)SNVLikely pathogenicrs1057519925GRCh37Chr 3, 178928079: 178928079
153PIK3CANM_ 006218.3(PIK3CA): c.1357G> C (p.Glu453Gln)SNVLikely pathogenicrs1057519925GRCh37Chr 3, 178928079: 178928079
154PIK3CANM_ 006218.3(PIK3CA): c.1359A> T (p.Glu453Asp)SNVLikely pathogenicrs1057519926GRCh37Chr 3, 178928081: 178928081
155PIK3CANM_ 006218.3(PIK3CA): c.1625A> C (p.Glu542Ala)SNVLikely pathogenicrs1057519927GRCh37Chr 3, 178936083: 178936083
156PIK3CANM_ 006218.3(PIK3CA): c.1625A> T (p.Glu542Val)SNVLikely pathogenicrs1057519927GRCh37Chr 3, 178936083: 178936083
157PIK3CANM_ 006218.3(PIK3CA): c.1625A> G (p.Glu542Gly)SNVLikely pathogenicrs1057519927GRCh37Chr 3, 178936083: 178936083
158PIK3CANM_ 006218.3(PIK3CA): c.2176G> A (p.Glu726Lys)SNVPathogenic/ Likely pathogenicrs867262025GRCh37Chr 3, 178938934: 178938934
159PIK3CANM_ 006218.3(PIK3CA): c.2177A> C (p.Glu726Ala)SNVLikely pathogenicrs1057519928GRCh37Chr 3, 178938935: 178938935
160PIK3CANM_ 006218.3(PIK3CA): c.241G> A (p.Glu81Lys)SNVLikely pathogenicrs1057519929GRCh37Chr 3, 178916854: 178916854
161PIK3CANM_ 006218.3(PIK3CA): c.3141T> G (p.His1047Gln)SNVLikely pathogenicrs1057519932GRCh37Chr 3, 178952086: 178952086
162PIK3CANM_ 006218.3(PIK3CA): c.331A> G (p.Lys111Glu)SNVLikely pathogenicrs1057519933GRCh37Chr 3, 178916944: 178916944
163PIK3CANM_ 006218.3(PIK3CA): c.333G> C (p.Lys111Asn)SNVLikely pathogenicrs1057519934GRCh37Chr 3, 178916946: 178916946
164PIK3CANM_ 006218.3(PIK3CA): c.332A> G (p.Lys111Arg)SNVLikely pathogenicrs1057519935GRCh37Chr 3, 178916945: 178916945
165PIK3CANM_ 006218.3(PIK3CA): c.3127A> G (p.Met1043Val)SNVLikely pathogenicrs1057519936GRCh37Chr 3, 178952072: 178952072
166PIK3CANM_ 006218.3(PIK3CA): c.3128T> C (p.Met1043Thr)SNVLikely pathogenicrs1057519937GRCh37Chr 3, 178952073: 178952073
167PIK3CANM_ 006218.3(PIK3CA): c.3127A> T (p.Met1043Leu)SNVLikely pathogenicrs1057519936GRCh37Chr 3, 178952072: 178952072
168PIK3CANM_ 006218.3(PIK3CA): c.1034A> T (p.Asn345Ile)SNVLikely pathogenicrs1057519938GRCh37Chr 3, 178921552: 178921552
169PIK3CANM_ 006218.3(PIK3CA): c.1034A> C (p.Asn345Thr)SNVLikely pathogenicrs1057519938GRCh37Chr 3, 178921552: 178921552
170PIK3CANM_ 006218.3(PIK3CA): c.1033A> C (p.Asn345His)SNVLikely pathogenicrs1057519939GRCh37Chr 3, 178921551: 178921551
171PIK3CANM_ 006218.3(PIK3CA): c.1638G> T (p.Gln546His)SNVLikely pathogenicrs1057519940GRCh37Chr 3, 178936096: 178936096
172PIK3CANM_ 006218.3(PIK3CA): c.1031T> G (p.Val344Gly)SNVLikely pathogenicrs1057519941GRCh37Chr 3, 178921549: 178921549
173PIK3CANM_ 006218.3(PIK3CA): c.1030G> A (p.Val344Met)SNVLikely pathogenicrs1057519942GRCh37Chr 3, 178921548: 178921548
174PIK3CANM_ 006218.3(PIK3CA): c.1031T> C (p.Val344Ala)SNVLikely pathogenicrs1057519941GRCh37Chr 3, 178921549: 178921549
175PPP2R1ANM_ 014225.5(PPP2R1A): c.547C> T (p.Arg183Trp)SNVLikely pathogenicrs1057519946GRCh37Chr 19, 52715982: 52715982
176PPP2R1ANM_ 014225.5(PPP2R1A): c.548G> A (p.Arg183Gln)SNVLikely pathogenicrs1057519947GRCh37Chr 19, 52715983: 52715983
177PPP2R1ANM_ 014225.5(PPP2R1A): c.547C> G (p.Arg183Gly)SNVLikely pathogenicrs1057519946GRCh37Chr 19, 52715982: 52715982
178PTENNM_ 000314.6(PTEN): c.389G> T (p.Arg130Leu)SNVPathogenic/ Likely pathogenicrs121909229GRCh37Chr 10, 89692905: 89692905
179RAC1NM_ 018890.3(RAC1): c.86C> T (p.Pro29Leu)SNVLikely pathogenicrs1057519948GRCh37Chr 7, 6426893: 6426893
180RAC1NM_ 018890.3(RAC1): c.85C> A (p.Pro29Thr)SNVLikely pathogenicrs1057519874GRCh37Chr 7, 6426892: 6426892
181RHOANM_ 001664.3(RHOA): c.118G> C (p.Glu40Gln)SNVLikely pathogenicrs1057519951GRCh37Chr 3, 49412905: 49412905
182RHOANM_ 001664.3(RHOA): c.118G> A (p.Glu40Lys)SNVLikely pathogenicrs1057519951GRCh37Chr 3, 49412905: 49412905
183RHOANM_ 001664.3(RHOA): c.125A> G (p.Tyr42Cys)SNVLikely pathogenicrs1057519954GRCh37Chr 3, 49412898: 49412898
184RHOANM_ 001664.3(RHOA): c.125A> C (p.Tyr42Ser)SNVLikely pathogenicrs1057519954GRCh37Chr 3, 49412898: 49412898
185RHOANM_ 001664.3(RHOA): c.125A> T (p.Tyr42Phe)SNVLikely pathogenicrs1057519954GRCh37Chr 3, 49412898: 49412898
186SMAD4NM_ 005359.5(SMAD4): c.1082G> C (p.Arg361Pro)SNVLikely pathogenicrs377767347GRCh37Chr 18, 48591919: 48591919
187TP53NM_ 001126113.2(TP53): c.421T> C (p.Cys141Arg)SNVLikely pathogenicrs1057519978GRCh37Chr 17, 7578509: 7578509
188TP53NM_ 001126115.1(TP53): c.25T> G (p.Cys9Gly)SNVLikely pathogenicrs1057519978GRCh37Chr 17, 7578509: 7578509
189TP53NM_ 000546.5(TP53): c.421T> A (p.Cys141Ser)SNVLikely pathogenicrs1057519978GRCh37Chr 17, 7578509: 7578509
190TP53NM_ 001126114.2(TP53): c.422G> T (p.Cys141Phe)SNVLikely pathogenicrs587781288GRCh37Chr 17, 7578508: 7578508
191TP53NM_ 001126114.2(TP53): c.527G> T (p.Cys176Phe)SNVLikely pathogenicrs786202962GRCh37Chr 17, 7578403: 7578403
192TP53NM_ 001126117.1(TP53): c.130T> A (p.Cys44Ser)SNVLikely pathogenicrs967461896GRCh37Chr 17, 7578404: 7578404
193TP53NM_ 001126117.1(TP53): c.130T> G (p.Cys44Gly)SNVLikely pathogenicrs967461896GRCh37Chr 17, 7578404: 7578404
194TP53NM_ 001126112.2(TP53): c.528C> G (p.Cys176Trp)SNVLikely pathogenicrs1057519980GRCh37Chr 17, 7578402: 7578402
195TP53NM_ 001126117.1(TP53): c.130T> C (p.Cys44Arg)SNVLikely pathogenicrs967461896GRCh37Chr 17, 7578404: 7578404
196TP53NM_ 000546.5(TP53): c.713G> T (p.Cys238Phe)SNVPathogenic/ Likely pathogenicrs730882005GRCh37Chr 17, 7577568: 7577568
197TP53NM_ 000546.5(TP53): c.713G> C (p.Cys238Ser)SNVLikely pathogenicrs730882005GRCh37Chr 17, 7577568: 7577568
198TP53NM_ 001126117.1(TP53): c.316T> C (p.Cys106Arg)SNVLikely pathogenicrs1057519981GRCh37Chr 17, 7577569: 7577569
199TP53NM_ 001126115.1(TP53): c.316T> G (p.Cys106Gly)SNVLikely pathogenicrs1057519981GRCh37Chr 17, 7577569: 7577569
200TP53NM_ 001126113.2(TP53): c.725G> T (p.Cys242Phe)SNVLikely pathogenicrs121912655GRCh37Chr 17, 7577556: 7577556
201TP53NM_ 001126115.1(TP53): c.328T> A (p.Cys110Ser)SNVLikely pathogenicrs1057519982GRCh37Chr 17, 7577557: 7577557
202TP53NM_ 001126116.1(TP53): c.330C> G (p.Cys110Trp)SNVLikely pathogenicrs375874539GRCh37Chr 17, 7577555: 7577555
203TP53NM_ 001126117.1(TP53): c.428G> T (p.Cys143Phe)SNVLikely pathogenicrs863224451GRCh37Chr 17, 7577114: 7577114
204TP53NM_ 001126112.2(TP53): c.824G> C (p.Cys275Ser)SNVLikely pathogenicrs863224451GRCh37Chr 17, 7577114: 7577114
205TP53NM_ 001126112.2(TP53): c.823T> C (p.Cys275Arg)SNVLikely pathogenicrs1057519983GRCh37Chr 17, 7577115: 7577115
206TP53NM_ 001126116.1(TP53): c.445G> T (p.Asp149Tyr)SNVLikely pathogenicrs764146326GRCh37Chr 17, 7577097: 7577097
207TP53NM_ 001126116.1(TP53): c.445G> A (p.Asp149Asn)SNVLikely pathogenicrs764146326GRCh37Chr 17, 7577097: 7577097
208TP53NM_ 001126117.1(TP53): c.447C> G (p.Asp149Glu)SNVLikely pathogenicrs1057519984GRCh37Chr 17, 7577095: 7577095
209TP53NM_ 001126115.1(TP53): c.445G> C (p.Asp149His)SNVLikely pathogenicrs764146326GRCh37Chr 17, 7577097: 7577097
210TP53NM_ 001126117.1(TP53): c.446A> C (p.Asp149Ala)SNVLikely pathogenicrs587781525GRCh37Chr 17, 7577096: 7577096
211TP53NM_ 001126113.2(TP53): c.857A> G (p.Glu286Gly)SNVLikely pathogenicrs1057519985GRCh37Chr 17, 7577081: 7577081
212TP53NM_ 001126117.1(TP53): c.460G> C (p.Glu154Gln)SNVLikely pathogenicrs786201059GRCh37Chr 17, 7577082: 7577082
213TP53NM_ 001126117.1(TP53): c.461A> T (p.Glu154Val)SNVLikely pathogenicrs1057519985GRCh37Chr 17, 7577081: 7577081
214TP53NM_ 000546.5(TP53): c.857A> C (p.Glu286Ala)SNVLikely pathogenicrs1057519985GRCh37Chr 17, 7577081: 7577081
215TP53NM_ 000546.5(TP53): c.809T> C (p.Phe270Ser)SNVLikely pathogenicrs1057519986GRCh38Chr 17, 7673811: 7673811
216TP53NM_ 001126117.1(TP53): c.414T> G (p.Phe138Leu)SNVLikely pathogenicrs1057519987GRCh37Chr 17, 7577128: 7577128
217TP53NM_ 001126113.2(TP53): c.808T> A (p.Phe270Ile)SNVLikely pathogenicrs1057519988GRCh37Chr 17, 7577130: 7577130
218TP53NM_ 001126114.2(TP53): c.809T> G (p.Phe270Cys)SNVLikely pathogenicrs1057519986GRCh37Chr 17, 7577129: 7577129
219TP53NM_ 001126115.1(TP53): c.412T> G (p.Phe138Val)SNVLikely pathogenicrs1057519988GRCh37Chr 17, 7577130: 7577130
220TP53NM_ 001126113.2(TP53): c.730G> T (p.Gly244Cys)SNVLikely pathogenicrs1057519989GRCh37Chr 17, 7577551: 7577551
221TP53NM_ 001126116.1(TP53): c.334G> A (p.Gly112Ser)SNVLikely pathogenicrs1057519989GRCh37Chr 17, 7577551: 7577551
222TP53NM_ 001126118.1(TP53): c.614G> T (p.Gly205Val)SNVLikely pathogenicrs985033810GRCh37Chr 17, 7577550: 7577550
223TP53NM_ 001126115.1(TP53): c.334G> C (p.Gly112Arg)SNVLikely pathogenicrs1057519989GRCh37Chr 17, 7577551: 7577551
224TP53NM_ 000546.5(TP53): c.734G> T (p.Gly245Val)SNVLikely pathogenicrs121912656GRCh37Chr 17, 7577547: 7577547
225TP53NM_ 001126116.1(TP53): c.337G> C (p.Gly113Arg)SNVLikely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
226TP53NM_ 001126115.1(TP53): c.400G> C (p.Gly134Arg)SNVLikely pathogenicrs1057519990GRCh37Chr 17, 7577142: 7577142
227TP53NM_ 001126113.2(TP53): c.536A> G (p.His179Arg)SNVLikely pathogenicrs1057519991GRCh37Chr 17, 7578394: 7578394
228TP53NM_ 001126117.1(TP53): c.141T> G (p.His47Gln)SNVLikely pathogenicrs876660821GRCh37Chr 17, 7578393: 7578393
229TP53NM_ 001126118.1(TP53): c.419A> T (p.His140Leu)SNVLikely pathogenicrs1057519991GRCh37Chr 17, 7578394: 7578394
230TP53NM_ 001126118.1(TP53): c.418C> A (p.His140Asn)SNVLikely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
231TP53NM_ 001126118.1(TP53): c.418C> G (p.His140Asp)SNVLikely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
232TP53NM_ 001126117.1(TP53): c.140A> C (p.His47Pro)SNVLikely pathogenicrs1057519991GRCh37Chr 17, 7578394: 7578394
233TP53NM_ 001126115.1(TP53): c.182A> C (p.His61Pro)SNVLikely pathogenicrs786201838GRCh37Chr 17, 7578271: 7578271
234TP53NM_ 000546.5(TP53): c.577C> G (p.His193Asp)SNVLikely pathogenicrs876658468GRCh37Chr 17, 7578272: 7578272
235TP53NM_ 001126113.2(TP53): c.577C> A (p.His193Asn)SNVLikely pathogenicrs876658468GRCh37Chr 17, 7578272: 7578272
236TP53NM_ 001126115.1(TP53): c.187A> T (p.Ile63Phe)SNVLikely pathogenicrs942158624GRCh37Chr 17, 7578266: 7578266
237TP53NM_ 001126118.1(TP53): c.467T> A (p.Ile156Asn)SNVLikely pathogenicrs760043106GRCh37Chr 17, 7578265: 7578265
238TP53NM_ 001126116.1(TP53): c.188T> G (p.Ile63Ser)SNVLikely pathogenicrs760043106GRCh37Chr 17, 7578265: 7578265
239TP53NM_ 001126116.1(TP53): c.189C> G (p.Ile63Met)SNVLikely pathogenicrs1057519994GRCh37Chr 17, 7578264: 7578264
240TP53NM_ 000546.5(TP53): c.396G> C (p.Lys132Asn)SNVLikely pathogenicrs866775781GRCh37Chr 17, 7578534: 7578534
241TP53NM_ 001126112.2(TP53): c.395A> C (p.Lys132Thr)SNVLikely pathogenicrs1057519996GRCh37Chr 17, 7578535: 7578535
242TP53NM_ 001126112.2(TP53): c.394A> C (p.Lys132Gln)SNVLikely pathogenicrs747342068GRCh37Chr 17, 7578536: 7578536
243TP53NM_ 000546.5(TP53): c.395A> T (p.Lys132Met)SNVLikely pathogenicrs1057519996GRCh37Chr 17, 7578535: 7578535
244TP53NM_ 000546.5(TP53): c.581T> G (p.Leu194Arg)SNVLikely pathogenicrs1057519998GRCh37Chr 17, 7578268: 7578268
245TP53NM_ 001126113.2(TP53): c.581T> A (p.Leu194His)SNVLikely pathogenicrs1057519998GRCh37Chr 17, 7578268: 7578268
246TP53NM_ 000546.5(TP53): c.581T> C (p.Leu194Pro)SNVLikely pathogenicrs1057519998GRCh37Chr 17, 7578268: 7578268
247TP53NM_ 001126113.2(TP53): c.710T> A (p.Met237Lys)SNVLikely pathogenicrs765848205GRCh37Chr 17, 7577571: 7577571
248TP53NM_ 001126115.1(TP53): c.320A> G (p.Asn107Ser)SNVLikely pathogenicrs1057519999GRCh37Chr 17, 7577565: 7577565
249TP53NM_ 001126114.2(TP53): c.716A> C (p.Asn239Thr)SNVLikely pathogenicrs1057519999GRCh37Chr 17, 7577565: 7577565
250TP53NM_ 001126112.2(TP53): c.452C> A (p.Pro151His)SNVLikely pathogenicrs1057520000GRCh37Chr 17, 7578478: 7578478
251TP53NM_ 001126115.1(TP53): c.56C> G (p.Pro19Arg)SNVLikely pathogenicrs1057520000GRCh37Chr 17, 7578478: 7578478
252TP53NM_ 001126115.1(TP53): c.436C> T (p.Pro146Ser)SNVLikely pathogenicrs17849781GRCh37Chr 17, 7577106: 7577106
253TP53NM_ 001126117.1(TP53): c.436C> A (p.Pro146Thr)SNVLikely pathogenicrs17849781GRCh37Chr 17, 7577106: 7577106
254TP53NM_ 001126114.2(TP53): c.833C> G (p.Pro278Arg)SNVLikely pathogenicrs876659802GRCh37Chr 17, 7577105: 7577105
255TP53NM_ 001126114.2(TP53): c.832C> G (p.Pro278Ala)SNVLikely pathogenicrs17849781GRCh37Chr 17, 7577106: 7577106
256TP53NM_ 000546.5(TP53): c.833C> A (p.Pro278His)SNVLikely pathogenicrs876659802GRCh37Chr 17, 7577105: 7577105
257TP53NM_ 001126112.2(TP53): c.431A> T (p.Gln144Leu)SNVLikely pathogenicrs786203071GRCh37Chr 17, 7578499: 7578499
258TP53NM_ 001126118.1(TP53): c.315G> T (p.Gln105His)SNVLikely pathogenicrs786201419GRCh37Chr 17, 7578498: 7578498
259TP53NM_ 000546.5(TP53): c.523C> G (p.Arg175Gly)SNVPathogenic/ Likely pathogenicrs138729528GRCh37Chr 17, 7578407: 7578407
260TP53NM_ 001126114.2(TP53): c.638G> T (p.Arg213Leu)SNVLikely pathogenicrs587778720GRCh37Chr 17, 7578211: 7578211
261TP53NM_ 001126112.2(TP53): c.637C> G (p.Arg213Gly)SNVLikely pathogenicrs397516436GRCh37Chr 17, 7578212: 7578212
262TP53NM_ 000546.5(TP53): c.742C> G (p.Arg248Gly)SNVLikely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
263TP53NM_ 001126112.2(TP53): c.746G> T (p.Arg249Met)SNVLikely pathogenicrs587782329GRCh37Chr 17, 7577535: 7577535
264TP53NM_ 001126112.2(TP53): c.818G> T (p.Arg273Leu)SNVLikely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
265TP53NM_ 001126112.2(TP53): c.817C> A (p.Arg273Ser)SNVLikely pathogenicrs121913343GRCh37Chr 17, 7577121: 7577121
266TP53NM_ 000546.5(TP53): c.839G> A (p.Arg280Lys)SNVLikely pathogenicrs121912660GRCh37Chr 17, 7577099: 7577099
267TP53NM_ 001126113.2(TP53): c.838A> G (p.Arg280Gly)SNVLikely pathogenicrs753660142GRCh37Chr 17, 7577100: 7577100
268TP53NM_ 001126112.2(TP53): c.845G> C (p.Arg282Pro)SNVLikely pathogenicrs730882008GRCh37Chr 17, 7577093: 7577093
269TP53NM_ 001126117.1(TP53): c.326C> A (p.Ser109Tyr)SNVLikely pathogenicrs28934573GRCh37Chr 17, 7577559: 7577559
270TP53NM_ 001126115.1(TP53): c.325T> C (p.Ser109Pro)SNVLikely pathogenicrs1057520002GRCh37Chr 17, 7577560: 7577560
271TP53NM_ 001126114.2(TP53): c.721T> G (p.Ser241Ala)SNVLikely pathogenicrs1057520002GRCh37Chr 17, 7577560: 7577560
272TP53NM_ 000546.5(TP53): c.373A> C (p.Thr125Pro)SNVLikely pathogenicrs1057520003GRCh37Chr 17, 7579314: 7579314
273TP53NM_ 001126113.2(TP53): c.374C> G (p.Thr125Arg)SNVLikely pathogenicrs786201057GRCh37Chr 17, 7579313: 7579313
274TP53NM_ 000546.5(TP53): c.517G> T (p.Val173Leu)SNVLikely pathogenicrs876660754GRCh37Chr 17, 7578413: 7578413
275TP53NM_ 001126113.2(TP53): c.518T> A (p.Val173Glu)SNVLikely pathogenicrs1057519747GRCh37Chr 17, 7578412: 7578412
276TP53NM_ 001126117.1(TP53): c.250G> T (p.Val84Leu)SNVLikely pathogenicrs730882025GRCh38Chr 17, 7674885: 7674885
277TP53NM_ 001126117.1(TP53): c.251T> G (p.Val84Gly)SNVLikely pathogenicrs1057520004GRCh37Chr 17, 7578202: 7578202
278TP53NM_ 001126116.1(TP53): c.251T> A (p.Val84Glu)SNVLikely pathogenicrs1057520004GRCh37Chr 17, 7578202: 7578202
279TP53NM_ 001126116.1(TP53): c.419T> A (p.Val140Glu)SNVLikely pathogenicrs876660333GRCh37Chr 17, 7577123: 7577123
280TP53NM_ 001126115.1(TP53): c.91T> A (p.Tyr31Asn)SNVLikely pathogenicrs786203436GRCh37Chr 17, 7578443: 7578443
281TP53NM_ 001126112.2(TP53): c.487T> C (p.Tyr163His)SNVLikely pathogenicrs786203436GRCh37Chr 17, 7578443: 7578443
282TP53NM_ 001126118.1(TP53): c.497A> G (p.Tyr166Cys)SNVLikely pathogenicrs1057520007GRCh37Chr 17, 7578235: 7578235
283TP53NM_ 001126117.1(TP53): c.218A> T (p.Tyr73Phe)SNVLikely pathogenicrs1057520007GRCh37Chr 17, 7578235: 7578235
284TP53NM_ 001126118.1(TP53): c.497A> C (p.Tyr166Ser)SNVLikely pathogenicrs1057520007GRCh37Chr 17, 7578235: 7578235
285TP53NM_ 001126113.2(TP53): c.613T> A (p.Tyr205Asn)SNVLikely pathogenicrs1057520008GRCh37Chr 17, 7578236: 7578236
286TP53NM_ 000546.5(TP53): c.613T> C (p.Tyr205His)SNVLikely pathogenicrs1057520008GRCh37Chr 17, 7578236: 7578236
287TP53NM_ 000546.5(TP53): c.658T> C (p.Tyr220His)SNVLikely pathogenicrs530941076GRCh37Chr 17, 7578191: 7578191
288TP53NM_ 001126118.1(TP53): c.541T> A (p.Tyr181Asn)SNVLikely pathogenicrs530941076GRCh37Chr 17, 7578191: 7578191
289TP53NM_ 000546.5(TP53): c.658T> G (p.Tyr220Asp)SNVLikely pathogenicrs530941076GRCh37Chr 17, 7578191: 7578191
290TP53NM_ 001126114.2(TP53): c.701A> C (p.Tyr234Ser)SNVLikely pathogenicrs587780073GRCh37Chr 17, 7577580: 7577580
291TP53NM_ 001126113.2(TP53): c.700T> C (p.Tyr234His)SNVLikely pathogenicrs864622237GRCh37Chr 17, 7577581: 7577581
292TP53NM_ 000546.5(TP53): c.700T> A (p.Tyr234Asn)SNVLikely pathogenicrs864622237GRCh37Chr 17, 7577581: 7577581
293TP53NM_ 001126115.1(TP53): c.311A> G (p.Tyr104Cys)SNVLikely pathogenicrs730882026GRCh37Chr 17, 7577574: 7577574
294PIK3CANM_ 006218.3(PIK3CA): c.3139C> T (p.His1047Tyr)SNVPathogenic/ Likely pathogenicrs121913281GRCh37Chr 3, 178952084: 178952084
295BRAFNM_ 004333.4(BRAF): c.1780G> A (p.Asp594Asn)SNVPathogenic/ Likely pathogenicrs397516896GRCh37Chr 7, 140453155: 140453155
296EGFRNM_ 005228.4(EGFR): c.2155G> C (p.Gly719Arg)SNVLikely pathogenic, drug responsers28929495GRCh37Chr 7, 55241707: 55241707
297PIK3CANM_ 006218.3(PIK3CA): c.1637A> G (p.Gln546Arg)SNVPathogenic/ Likely pathogenicrs397517201GRCh37Chr 3, 178936095: 178936095
298TNFRSF10BTNFRSF10B, 2-BP INSinsertionPathogenic
299FBXW7NM_ 033632.3(FBXW7): c.1513C> T (p.Arg505Cys)SNVLikely pathogenicrs149680468GRCh37Chr 4, 153247289: 153247289
300CDKN2ANM_ 000077.4(CDKN2A): c.341C> T (p.Pro114Leu)SNVLikely pathogenicrs121913386GRCh37Chr 9, 21971017: 21971017
301PTENNM_ 000314.6(PTEN): c.389G> A (p.Arg130Gln)SNVPathogenic/ Likely pathogenicrs121909229GRCh37Chr 10, 89692905: 89692905
302PTENNM_ 000314.6(PTEN): c.362C> G (p.Ala121Gly)SNVPathogenicrs121909237GRCh37Chr 10, 89692878: 89692878
303ING1NM_ 198217.2(ING1): c.512G> C (p.Cys171Ser)SNVPathogenicrs121909250GRCh37Chr 13, 111372083: 111372083
304ING1NM_ 198217.2(ING1): c.515A> G (p.Asn172Ser)SNVPathogenicrs121909251GRCh37Chr 13, 111372086: 111372086
305ING1NM_ 198217.2(ING1): c.443C> A (p.Ala148Asp)SNVPathogenicrs121909252GRCh37Chr 13, 111372014: 111372014
306MAP2K2NM_ 030662.3(MAP2K2): c.169T> G (p.Phe57Val)SNVPathogenic/ Likely pathogenicrs121434498GRCh37Chr 19, 4117551: 4117551
307SMAD4NM_ 005359.5(SMAD4): c.1081C> T (p.Arg361Cys)SNVPathogenic/ Likely pathogenicrs80338963GRCh37Chr 18, 48591918: 48591918

Cosmic variations for Squamous Cell Carcinoma, Head and Neck:

8 (show top 50)    (show all 362)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM14452PTCH1skin,neck,carcinoma,NSc.2321G>Ap.G774E48
2COSM29072PTCH1skin,neck,carcinoma,NSc.1067+1G>Ap.?48
3COSM29053PTCH1skin,neck,carcinoma,NSc.833G>Ap.W278*48
4COSM498HRASskin,neck,carcinoma,squamous cell carcinoma BRAF inhibitor relatedc.182A>Tp.Q61L48
5COSM516KRASskin,neck,carcinoma,NSc.34G>Tp.G12C48
6COSM17483PTCH1skin,neck,carcinoma,NSc.1729-1G>Tp.?48
7COSM17468PTCH1skin,neck,carcinoma,NSc.584G>Tp.R195M48
8COSM6240EGFRupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.2369C>Tp.T790M38
9COSM99622NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.4016G>Cp.G1339A38
10COSM44310TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.738G>Ap.M246I38
11COSM10648TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.524G>Ap.R175H38
12COSM11196TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.734G>Tp.G245V38
13COSM763PIK3CAupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.1633G>Ap.E545K38
14COSM24802FGFR3upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.2089G>Tp.G697C38
15COSM33692HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.185A>Gp.E62G38
16COSM43947TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.614A>Gp.Y205C38
17COSM44393TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.821T>Cp.V274A38
18COSM764PIK3CAupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.1634A>Gp.E545G38
19COSM43582TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.454C>Tp.P152S38
20COSM483HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.35G>Tp.G12V38
21COSM29446FGFR3upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.753C>Tp.H251H38
22COSM44226TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.380C>Tp.S127F38
23COSM99653NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.3835C>Tp.R1279C38
24COSM10654TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.637C>Tp.R213*38
25COSM10704TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.844C>Tp.R282W38
26COSM10672TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.577C>Tp.H193Y38
27COSM10941TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.730G>Ap.G244S38
28COSM10656TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.742C>Tp.R248W38
29COSM10728TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.839G>Ap.R280K38
30COSM43635TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.536A>Tp.H179L38
31COSM1667029NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.666C>Ap.C222*38
32COSM44126TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.507G>Ap.M169I38
33COSM10790TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.455C>Tp.P152L38
34COSM43868TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.689C>Tp.T230I38
35COSM12504CDKN2Aupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.247C>Tp.H83Y38
36COSM44335TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.958A>Tp.K320*38
37COSM44091TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.746G>Ap.R249K38
38COSM11063TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.711G>Tp.M237I38
39COSM1737921CDKN2Aupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.124A>Cp.N42H38
40COSM44577TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.921A>Gp.A307A38
41COSM3722007HCN1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.808C>Tp.R270*38
42COSM488HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.37G>Tp.G13C38
43COSM99939NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.5529G>Ap.W1843*38
44COSM10834TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.711G>Ap.M237I38
45COSM45099TP53upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.924G>Ap.L308L38
46COSM3724382NOTCH1upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.6738C>Gp.H2246Q38
47COSM521KRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.35G>Ap.G12D38
48COSM3724387CASP8upper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.415C>Tp.Q139*38
49COSM480HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.34G>Ap.G12S38
50COSM481HRASupper aerodigestive tract,mouth,carcinoma,squamous cell carcinomac.34G>Tp.G12C38

Copy number variations for Squamous Cell Carcinoma, Head and Neck from CNVD:

6 (show all 42)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
13395215070000061300000Amplificationhead and neck squamous cell carcinoma
271135126770000071500000Amplificationhead and neck squamous cell carcinoma
378639135530000073300000Amplificationhead and neck squamous cell carcinoma
490904152570000028100000Amplificationhead and neck squamous cell carcinoma
593784155910000059300000Copy numberMEThead and neck squamous cell carcinoma
61180061775058217531588LOHTP53head and neck squamous cell carcinoma
71191921817100000Amplificationhead and neck squamous cell carcinoma
8119790181720000019000000Amplificationhead and neck squamous cell carcinoma
91661343187900000Losshead and neck squamous cell carcinoma
101676353121900000167600000Gainhead and neck squamous cell carcinoma
111695563142800000148900000Amplificationhead and neck squamous cell carcinoma
121714863168801287168851758AmplificationEVI1head and neck squamous cell carcinoma
131714953168867391169381563AmplificationMDS1head and neck squamous cell carcinoma
141724873182700000187900000AmplificationRFC4head and neck squamous cell carcinoma
151747461277732777793336DeletionDLEChead and neck squamous cell carcinoma
16179443391000000121900000Gainhead and neck squamous cell carcinoma
171799734150400000Losshead and neck squamous cell carcinoma
182047366114600000171115067Gainhead and neck squamous cell carcinoma
1921704971159138663Copy numberhead and neck squamous cell carcinoma
2022536974540000054000000GainEGFRhead and neck squamous cell carcinoma
2122538374540000054000000AmplificationEGFRhead and neck squamous cell carcinoma
2222540374540000054000000Copy numberEGFRhead and neck squamous cell carcinoma
2322540474540000054000000Copy numberEGFRhead and neck squamous cell carcinoma
2422540874540000054000000Deletion or amplific ationEGFRhead and neck squamous cell carcinoma
2522541374540000058000000Amplificationhead and neck squamous cell carcinoma
2622653275800000059900000Amplificationhead and neck squamous cell carcinoma
272327478119200000122500000GainMYChead and neck squamous cell carcinoma
282337698127300000139900000GainKHDRBS3head and neck squamous cell carcinoma
292348768139900000146364022GainFAKhead and neck squamous cell carcinoma
302348958139900000146364022GainPTP4A3head and neck squamous cell carcinoma
3123801182880000045600000Amplificationhead and neck squamous cell carcinoma
3223998884310000045600000Amplificationhead and neck squamous cell carcinoma
33240109845600000146364022GainGAA1head and neck squamous cell carcinoma
3424189986800000070500000Amplificationhead and neck squamous cell carcinoma
35243677886900000101600000AmplificationRUNX1T1head and neck squamous cell carcinoma
3624998491990000025500000DeletionCDKN2Ahead and neck squamous cell carcinoma
37300518119535108795715992MethylationMAML2head and neck squamous cell carcinoma
3830053012123374913123617963MethylationNCOR2head and neck squamous cell carcinoma
39300892147267293172756862MethylationPSEN1head and neck squamous cell carcinoma
40300893147281167072995039MethylationNUMBhead and neck squamous cell carcinoma
41302931194586365145888396MethylationNUMBLhead and neck squamous cell carcinoma
42303261201056633110602694MethylationJAG1head and neck squamous cell carcinoma

Expression for genes affiliated with Squamous Cell Carcinoma, Head and Neck

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Squamous Cell Carcinoma, Head and Neck patients vs. healthy controls: 35 (show all 15)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1MMP1matrix metallopeptidase 1Head Mesenchyme+5.250.000
2TMPRSS11Btransmembrane protease, serine 11BHead Mesenchyme-4.810.000
3CRISP3cysteine-rich secretory protein 3Head Mesenchyme-4.480.000
4MALmal, T-cell differentiation proteinHead Mesenchyme-4.390.000
5INHBAinhibin, beta AHead Mesenchyme+4.130.000
6CRNNcornulinHead Mesenchyme-4.000.000
7KRT17keratin 17, type IHead Mesenchyme+3.940.000
8KRT4keratin 4, type IIHead Mesenchyme-3.410.000
9PTHLHparathyroid hormone-like hormoneHead Mesenchyme+3.360.000
10CTHRC1collagen triple helix repeat containing 1Head Mesenchyme+3.320.000
11CLCA4chloride channel accessory 4Head Mesenchyme-3.310.000
12WDR72WD repeat domain 72Head Mesenchyme+3.230.000
13MMP10matrix metallopeptidase 10Head Mesenchyme+3.140.001
14TGM3transglutaminase 3Head Mesenchyme-3.080.000
15GBP1guanylate binding protein 1, interferon-inducibleHead Mesenchyme+3.060.000

Search GEO for disease gene expression data for Squamous Cell Carcinoma, Head and Neck.

Pathways for genes affiliated with Squamous Cell Carcinoma, Head and Neck

About this section

Pathways related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show top 50)    (show all 79)
idSuper pathwaysScoreTop Affiliating Genes
110.3CDKN2A, TP53, VEGFA
2
Show member pathways
10.3CCND1, EGFR, VEGFA
310.2PIK3CA, PTEN, TP53
410.2CCND1, STAT3, VEGFA
510.2CCND1, CDH1, TP53
610.2PIK3CA, PTEN, STAT3
710.2CDKN2A, PIK3CA, TP53
810.2EGFR, PIK3CA, STAT3
910.2EGFR, PIK3CA, STAT3
1010.2EGFR, MMP2, MMP9
11
Show member pathways
10.2CCND1, PIK3CA, STAT3
1210.2CCND1, MMP2, MMP9
1310.2CDH1, EGFR, PIK3CA
1410.2CDH1, EGFR, PIK3CA
15
Show member pathways
10.2CCND1, PTEN, TNFRSF10B, TP53
1610.2CDH1, CTTN, PIK3CA
17
Show member pathways
10.2CCND1, EGFR, PTEN, TP53
18
Show member pathways
10.2CCND1, CDKN2A, PTEN, TP53
1910.2MMP9, PIK3CA, STAT3
20
Show member pathways
10.2MMP9, PIK3CA, VEGFA
2110.2CCND1, EGFR, PTEN, STAT3
2210.2MMP2, MMP9, PIK3CA
2310.2EGFR, PIK3CA, PTEN, TP53
2410.2CCND1, PIK3CA, PTEN, TP53
2510.2CCND1, PIK3CA, PTEN, TP53
26
Show member pathways
10.2EGFR, PIK3CA, PTEN, STAT3
27
Show member pathways
10.2CCND1, CDH1, CDKN2A, TP53
2810.2CDKN2A, MMP2, TP53, VEGFA
2910.2CCND1, EGFR, MMP9, TP53
30
Show member pathways
10.2EGFR, PIK3CA, STAT3, TP53
3110.2EGFR, PIK3CA, STAT3, TP53
32
Show member pathways
10.1EGFR, PIK3CA, STAT3, VEGFA
3310.1EGFR, PIK3CA, STAT3, VEGFA
3410.1EGFR, MMP2, MMP9, STAT3
3510.1CD44, PIK3CA, STAT3, TP53
3610.1CD44, EGFR, MMP2, MMP9
37
Show member pathways
10.1CCND1, CDKN2A, PTEN, TNFRSF10B, TP53
38
Show member pathways
10.1CCND1, MMP2, MMP9, VEGFA
3910.1CCND1, CDKN2A, EGFR, PTEN, TP53
4010.1CCND1, CDH1, CTTN, PIK3CA
41
Show member pathways
10.1CD44, PIK3CA, STAT3, VEGFA
4210.1EGFR, MMP2, PTEN, TNFRSF10B, TP53
4310.1CCND1, CDH1, MMP2, MMP9
4410.1CD44, CDH1, MMP2, MMP9
4510.1CDH1, CTTN, MMP9, PIK3CA
46
Show member pathways
10.1CD44, MMP2, MMP9, PIK3CA
4710.1CCND1, CDKN2A, EGFR, MMP2, TP53
4810.1CCND1, CDKN2A, PIK3CA, PTEN, TP53
49
Show member pathways
10.1CCND1, EGFR, PIK3CA, PTEN, STAT3
50
Show member pathways
10.1CCND1, PIK3CA, PTEN, STAT3, TP53

GO Terms for genes affiliated with Squamous Cell Carcinoma, Head and Neck

About this section

Biological processes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show all 21)
idNameGO IDScoreTop Affiliating Genes
1cellular response to leptin stimulusGO:004432011.1PTEN, STAT3
2mitotic G1 DNA damage checkpointGO:003157111.1CCND1, TP53
3liver developmentGO:000188911.0CCND1, EGFR, PIK3CA
4replicative senescenceGO:009039911.0CDKN2A, TP53
5regulation of mitochondrial membrane permeabilityGO:004690211.0STAT3, TP53
6response to leptinGO:004432110.9CCND1, STAT3
7angiogenesisGO:000152510.9MMP2, PIK3CA, PTEN, VEGFA
8phosphatidylinositol-mediated signalingGO:004801510.9EGFR, PIK3CA, PTEN, TP53
9leukocyte migrationGO:005090010.9CD44, MMP9, PIK3CA, TNFRSF10B
10extracellular matrix disassemblyGO:002261710.9CD44, CDH1, MMP2, MMP9
11positive regulation of peptidyl-serine phosphorylationGO:003313810.9CD44, PIK3CA, VEGFA
12cell proliferationGO:000828310.9EGFR, PTEN, RPS27, STAT3, TP53
13negative regulation of cell proliferationGO:000828510.9CDKN2A, ING1, PTEN, STAT3, TP53
14positive regulation of apoptotic processGO:004306510.8CDKN2A, ING3, MMP9, PTEN, TP53
15response to estradiolGO:003235510.8CCND1, EGFR, PTEN, STAT3
16positive regulation of protein phosphorylationGO:000193410.8CCND1, EGFR, MMP9, VEGFA
17positive regulation of cell proliferationGO:000828410.8CCND1, EGFR, PTEN, STAT3, VEGFA
18response to organic cyclic compoundGO:001407010.7CCND1, EGFR, PTEN, STAT3
19negative regulation of apoptotic processGO:004306610.7CD44, EGFR, MMP9, PTEN, STAT3, TP53
20response to UV-AGO:007014110.3CCND1, EGFR
21response to organic substanceGO:001003310.2CCND1, CDH1, PTEN, STAT3

Molecular functions related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1identical protein bindingGO:004280210.7EGFR, FHIT, MMP9, PTEN, STAT3, TP53
2protein kinase bindingGO:001990110.5CCND1, CDKN2A, EGFR, PTEN, STAT3, TP53
3protein phosphatase bindingGO:001990310.3EGFR, STAT3, TP53
4protein bindingGO:00055159.6CCND1, CD44, CDH1, CDKN2A, CTTN, CXCL14

Sources for Squamous Cell Carcinoma, Head and Neck

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet